

Richard Haynes

From: Catherine Adams <Catherine.Adams@hra.nhs.uk>
Sent: 16 April 2020 20:38
To: Cambridge East; peter.horby@ndm.ox.ac.uk; ctrg@admin.ox.ac.uk
Cc: nhsg.nrspcc@nhs.net; research.amendments@hscni.net; HCRW.amendments@wales.nhs.uk; Catherine Adams; Richard Haynes; Richard Haynes
Subject: REISSUED categorisation and implementation date - IRAS 281712. Amendment categorisation and implementation information

Amendment Categorisation and Implementation Information

Dear Peter Horby,

The below is the corrected implementation date of substantial amendment 3.

IRAS Project ID:	281712
REC Reference:	20/EE/0101
Short Study Title:	RECOVERY trial
Date complete amendment submission received:	15 April 2020
Sponsor Amendment Reference Number:	SA3
Sponsor Amendment Date:	14 April 2020
Amendment Type	Substantial
Outcome of HRA and HCRW Assessment	HRA and HCRW Approval for the amendment separately confirmed by email.
Implementation date in NHS organisations in England and Wales	7 days from date amendment information together with this email, is supplied to participating organisations (23rd April 2020)
Implementation date in NHS/HSC organisations in Northern Ireland, and/or Scotland	19/05/2020 (providing conditions are met)
For NHS/HSC R&D Office information	

Amendment Category	A
--------------------	---

Thank you for submitting an amendment to your project. We have now categorised your amendment and please find this, as well as other relevant information, in the table above.

What should I do next?

Please read the information in [IRAS](#), which provides you with information on how and when you can implement your amendment at NHS/HSC sites in each nation, and what actions you should take now.

If you have participating NHS/HSC organisations in any other UK nations please note that **we will** forward the amendment submission to the relevant national coordinating function(s).

If not already provided, please email to us any regulatory approvals (where applicable) once available.

When can I implement this amendment?

You may implement this amendment in line with the information in [IRAS](#). Please note that you may only implement changes described in the amendment notice.

Who should I contact if I have further questions about this amendment?

If you have any questions about this amendment please contact the relevant national coordinating centre for advice:

- England – amendments@hra.nhs.uk
- Northern Ireland – research.gateway@hscni.net
- Scotland – nhsq.NRSPCC@nhs.net
- Wales – HCRW.amendments@wales.nhs.uk

Additional information on the management of amendments can be found in the [IRAS guidance](#).

Please do not hesitate to contact me if you require further information.

Best Wishes

Catherine Adams
Approvals Manager
Health Research Authority

HRA, NHSBT Newcastle Blood Donor Centre, Holland Dr, Newcastle upon Tyne NE2 4NQ
0207 972 2503

E. Catherine.adams@hra.nhs.uk

W. www.hra.nhs.uk

For information on the HRA's work on Covid19 please visit this link: <https://www.hra.nhs.uk/about-us/news-updates/research-nhs-during-covid-19-pandemic/>

This message may contain confidential information. If you are not the intended recipient please inform the sender that you have received the message in error before deleting it. Please do not disclose, copy or distribute information in this e-mail or take any action in relation to its contents. To do so is strictly prohibited and may be unlawful. Thank you for your co-operation..
